| Pharmaceutical Information |
| Drug Name |
Caspofungin |
| Drug ID |
BADD_D00376 |
| Description |
Caspofungin (brand name Cancidas worldwide) is an antifungal drug and the first member of a new drug class called the echinocandins, as coined by Merck & Co., Inc. It is typically administered intravenously. It shows activity against infections with Aspergillus and Candida, and works by inhibiting β(1,3)-D-Glucan of the fungal cell wall. |
| Indications and Usage |
For the treatment of esophageal candidiasis and invasive aspergillosis in patients who are refractory to or intolerant of other therapies. |
| Marketing Status |
approved |
| ATC Code |
J02AX04 |
| DrugBank ID |
DB00520
|
| KEGG ID |
D07626
|
| MeSH ID |
D000077336
|
| PubChem ID |
2826718
|
| TTD Drug ID |
D00ZCN
|
| NDC Product Code |
Not Available |
| UNII |
F0XDI6ZL63
|
| Synonyms |
Caspofungin | Cancidas | MK 0991 | MK-0991 | MK0991 | Caspofungin MSD | L 743,872 | L-743,872 | L743,872 | L-743872 | L743872 | L 743872 | Caspofungin Acetate |
|
| Chemical Information |
| Molecular Formula |
C52H88N10O15 |
| CAS Registry Number |
162808-62-0 |
| SMILES |
CCC(C)CC(C)CCCCCCCCC(=O)NC1CC(C(NC(=O)C2C(CCN2C(=O)C(NC(=O)C(NC(=O)C3CC(CN3C(=O)
C(NC1=O)C(C)O)O)C(C(C4=CC=C(C=C4)O)O)O)C(CCN)O)O)NCCN)O |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
|
